Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
Scandiatransplant office, Aarhus, Denmark.
HLA. 2017 Jul;90(1):17-24. doi: 10.1111/tan.13046. Epub 2017 Apr 27.
Highly immunized patients are a challenge for organ transplantation programs. One way of increasing the likelihood of transplantation in this group of patients is to expand the possible donations by defining acceptable HLA mismatches. In the Scandiatransplant Acceptable Mismatch Program (STAMP), a de-centralized approach has been implemented in 2009.
The program has been improved during the years from utilizing HLA-A, -B, -DR matching only to include typing of all deceased donors for HLA-A, -B, -C, -DRB1 and -DQB1. The calculation of a transplantability score (TS) has been introduced in order to take both HLA and AB0 into consideration resulting in a more realistic picture of the transplantability chance.
Patients were selected for eligibility and results of immunisation status were prepared in each of the 9 tissue typing laboratories, while access to the program is finally governed by a common steering group of immunologists and clinicians.
In the period from March 2009 until February 2015, 96 patients were transplanted within this program. The mean recipient age was 49 years and 57% were females, 30% of the patients were first transplants and of these 93% were females. The majority of the patients had 2-5 HLA-A, -B. -DR mismatches. The allograft survival at 60 months was 79.1%. Applying the TS to the cohort confirmed that patients with a low TS score had longer waiting times.
The program has matured during the years and now proves to be a valid approach for transplanting highly immunized patients.
高度免疫化的患者对器官移植项目来说是一个挑战。增加这群患者接受移植机会的方法之一是通过定义可接受的 HLA 错配来扩大可能的供体来源。在 2009 年,Scandiatransplant Acceptable Mismatch Program (STAMP) 实施了一种分散式方法。
该项目在过去几年中得到了改进,从仅利用 HLA-A、-B、-DR 匹配,扩展到包括对所有已故供体进行 HLA-A、-B、-C、-DRB1 和 -DQB1 分型。引入了移植适任性评分 (TS) 的计算方法,以同时考虑 HLA 和 ABO,从而更真实地反映移植机会。
在 9 个组织配型实验室中,每个实验室都选择符合条件的患者,并准备其免疫状态的结果,而对该项目的访问最终由免疫学家和临床医生组成的共同指导小组管理。
在 2009 年 3 月至 2015 年 2 月期间,有 96 名患者在该项目中接受了移植。受体的平均年龄为 49 岁,女性占 57%,30%的患者是首次移植,其中 93%为女性。大多数患者有 2-5 个 HLA-A、-B、-DR 错配。60 个月时的移植物存活率为 79.1%。将 TS 应用于该队列证实,低 TS 评分的患者等待时间更长。
该项目在过去几年中已经成熟,现在证明是移植高度免疫化患者的有效方法。